Leveraging Bioanalysis to Accelerate Drug Development Programs: Challenges and Considerations

  • Free

Why attend?

From drug discovery, through to preclinical and clinical studies, understanding drug exposure and behaviour are imperative to dose selection, and accelerating drugs to clinic and commercialization. Bioanalysis is an integral part of the drug development process, particularly in early development where it is used to support preclinical and FIH studies to determine metabolic fate and pharmacokinetics of the drug.

Through the use of robust bioanalytical techniques, biological samples can be processed and analyzed to identify and quantify compounds of interest, such as small molecules and their metabolites, as well as peptides, proteins, nucleic acids and other analytes. Bioanalysis can be utilized as both a stand-alone service or part of a fully integrated development program, as it plays a pivotal part in providing important bioanalytical data that aids in the formulation design.

Delivering rapid bioanalytical data is critical when trying to rapidly get medicines to patients faster. At Quotient, we utilize a integrated approach, by combining bioanalysis with toxicokinetics and pharmacokinetics (TK/PK) reporting and human ADME, to streamline the drug development process and to ensure that critical decision-making data is rapidly processed, robust and reliable.

Join Quotient’s Vice President of Bioanalysis, Dr Stuart McDouggal, as he discusses how best to leverage bioanalysis within drug development programs to accelerate timelines & enhance the likelihood of clinical & commercial success.

This webinar will provide an in-depth look at key strategies, including:

  • Lifecycle and evolution of bioanalytical assay during a drug development program
  • Quality and compliance; understanding the regulatory requirements at each stage of development
  • Science & knowledge; the value that experienced method developers can add to a program to enhance sensitivity, selectivity & speed of assay
  • Experience & accountability; bioanalytical program managers leading trained and highly motivated bioanalysts to deliver on-time analysis and data of the highest quality
  • Future direction / new frontiers for bioanalysis


Select a speaker to learn more

Dr Stuart McDougall
VP Bioanalysis

Dr Stuart McDougall is the Vice President of Bioanalysis at Quotient Sciences. Stuart has over 29 years experience in the pharmaceutical industry within Metabolism, Pharmacokinetic and Bioanalysis roles. Previous relevant positions include global leader of Sanofi-Aventis bioanalytical strategy team and a member of Covance global bioanalytical leadership team. Stuart is a pharmacology graduate from the University of Dundee, a harmonization team leader for the Global Bioanalytical Consortium (GBC), represents Quotient on the European Bioanalytical Forum (EBF) and is an author and co-author of numerous scientific papers.

Next speaker

Contact us

If you want to become a sponsor, speak at an event or become a partner, leave a message at the "Partner with us" page and we will contact you as soon as possible.